Payment overview · 2025
General Payments
$945.28
57 reported records · 13 companies
Healthcare provider profile · identity verified
Laura Hatchman
Allopathic & Osteopathic Physicians|Internal Medicine · ONEIDA, TN · NPI 1427619402
Verified facts
What the public records show
CMS Open Payments records show Laura Hatchman received $945.28 in general payments during 2025 across 57 reported records.
GlaxoSmithKline, LLC. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $231.00 | 24.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $195.40 | 20.7% | 17 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $107.55 | 11.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.13 | 10.5% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $97.51 | 10.3% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $67.59 | 7.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.70 | 3.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.47 | 3.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.01 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.42 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.28 | 1.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.17 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.05 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $945.28 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $231.00 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.24 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $107.55 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $97.51 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.39 | 10 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $83.52 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.16 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.59 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.55 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.70 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 203 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 145 | 48 |
| Lisinopril | Lisinopril | 136 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 32 |
| Metformin Hcl | Metformin Hcl | 90 | 22 |
| Furosemide | Furosemide | 77 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 25 |
| Losartan Potassium | Losartan Potassium | 74 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 21 |
| Omeprazole | Omeprazole | 71 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 23 |
| Trazodone Hcl | Trazodone Hcl | 61 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 60 | 22 |
| Ozempic | Semaglutide | 58 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 19 |
| Mirtazapine | Mirtazapine | 55 | 16 |
| Potassium Chloride | Potassium Chloride | 49 | 16 |
| Montelukast Sodium | Montelukast Sodium | 48 | 16 |
| Meloxicam | Meloxicam | 47 | 19 |
| Tramadol Hcl | Tramadol Hcl | 47 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 34 |
| Metformin Hcl Er | Metformin Hcl | 46 | 17 |
| Prednisone | Prednisone | 46 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Famotidine | Famotidine | 45 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 12 |
| Baclofen | Baclofen | 40 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Sertraline Hcl | Sertraline Hcl | 30 | 12 |
| Naproxen | Naproxen | 29 | 15 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 11 |
| Allopurinol | Allopurinol | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | 11 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 12 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Atenolol | Atenolol | 13 | suppressed |
| Benlysta | Belimumab | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Flector | Diclofenac Epolamine | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $945.28 · 57 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, CAPLYTA, GVOKE HYPOPEN, Kerendia, MOUNJARO, Ozempic, QULIPTA, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error